A0829 - Prognostic factors for Overall Survival (OS) in patients receiving First-line (1L) Nivolumab plus Ipilimumab (NIVO+IPI) for advanced/metastatic Renal Cell Carcinoma (aRCC) in a real-world setting in Germany

Autor: Bedke, J., Grünwald, V., Müller-Huesmann, H., Belz, H., Von Der Heyde, E., Bögemann, M., Strauß, A., Vaz, L., Bluhmki, T., Herber, M., Groetzinger, S., Grimm, M-O.
Zdroj: In European Urology March 2024 85 Supplement 1:S1844-S1845
Databáze: ScienceDirect
Externí odkaz: